Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, phase 2 clinical trial aimed at evaluating the
efficacy and safety of the combination of bendamustine and brentuximab vedotin as a first
salvage therapy in patients with relapsed or refractory Hodgkin's lymphoma or PTCL.
A total of 25 patients with PTCL, and 40 with Hodgkin's lymphoma are expected to be treated
according to this treatment protocol.